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Abstract
Objective: Evidence of larger drug effects in highly standardized studies (efficacy) 
compared to clinical routine (effectiveness) is discussed as efficacy- effectiveness gap. 
This study aimed to quantify effect size differences of RCTs and non- RCTs in the 
treatment of depression with venlafaxine and duloxetine and to identify effect modi-
fying predictors.
Methods: A comprehensive systematic review and meta- analysis was conducted, 
including all prospective trials, which evaluated the treatment effects of duloxetine 
or venlafaxine in patients with depression. The primary outcome was the pre- post 
effect size after acute therapy, which were compared between RCTs and non- RCTs. 
Moreover, an exploratory analysis of predictors in a mixed meta- regression model 
within an information- theoretic approach was performed.
Results: 171 RCTs and 74 non- RCTs were included. The pre- post effect size differed 
significantly between RCTs and non- RCTs (−3.04 vs. −2.62, Δ = 0.41, p = 0.012, 
high heterogeneity). Study characteristics were very similar between RCTs and non- 
RCTs. Most important variables to predict effect sizes were ‘depression severity’, 
‘dose’ and ‘number of participants’.
Conclusion: Despite differences in effect sizes between RCTs and non- RCTs, study 
design is not clearly an important predictor for the effect sizes. Our results ques-
tion the common assumption that non- RCTs are generally better suited to describe a 
drug’s effectiveness in clinical practice than RCTs. Future studies and their reporting 
should put more emphasis on the description of external validity, in order to allow 
better assessments of clinical relevance.
K E Y W O R D S
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Summations
• RCTs showed higher effect sizes than non- RCTs, but the two study designs were 
very similar in most study characteristics.
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1 |  INTRODUCTION
A chasm between theoretical research results and practi-
cal implementation exists in many scientific disciplines.1- 5 
In psychiatric research, the gap between a drug’s effect in 
highly standardized clinical trials and those in clinical real- 
world practice is often discussed. The discrepancy between 
drug effects in randomized controlled trials (RCTs, ‘effi-
cacy’) and under clinical routine conditions (‘effectiveness’) 
is referred to as the efficacy- effectiveness gap.6- 8
The antidepressant efficacy of duloxetine and venlafaxine, 
two selective serotonin norepinephrine reuptake inhibitors 
(SNRIs), has been shown in various trials. A large network 
meta- analysis confirmed the superior efficacy of several an-
tidepressants over placebo, including duloxetine and venla-
faxine.9 Likewise, the efficacy of duloxetine and venlafaxine 
could be demonstrated in earlier meta- analyses with aggre-
gated data10- 12 and with individual patient data,13 while there 
is no meta- analytic study of the drugs’ effects under clinical 
routine conditions.
It is assumed that efficacy and effectiveness trials are 
distinguished by various characteristics. RCTs are usu-
ally highly standardized and follow strict protocols. They 
are the gold standard in pharmacological research and are 
highly associated with a drug’s ‘efficacy’. On the contrary, 
non- RCTs (ie observational or non- randomized trials) are 
thought to evaluate a drug’s effect in a setting that is closer 
to clinical practice and are therefore associated with its ‘ef-
fectiveness’. The high degree of standardization in RCTs 
aims at increasing internal validity.6,14 In contrast, effec-
tiveness studies are supposed to have more heterogeneous 
and more representative patient populations or more feasi-
ble and more pragmatic interventions. Thus, effectiveness 
trials should have higher external validity.14- 17 These dif-
ferences between RCTs and non- RCTs have been described 
anecdotally while systematic evaluations of such differ-
ences are rare.
Differences in study characteristics and samples ques-
tion the transferability of results of RCTs to clinical practice. 
Clinical practice guidelines are mainly based on findings 
from RCTs (efficacy), but put into action in clinical practice 
(effectiveness). So far, two studies were published in which 
treatment outcomes of antidepressants in RCTs and observa-
tional studies were compared. A meta- analysis of fluoxetine 
and venlafaxine studies revealed that response rates in RCTs 
were significantly higher than in observational studies.18 In 
addition, a comparison of meta- analytical data and routine 
outcome monitoring data of antidepressants and psychother-
apy showed that significantly more depressed participants 
remitted in RCTs than in clinical routine studies.19
These first findings indicate divergent treatment effects 
in efficacy and effectiveness trials. However, besides the 
studies published several years ago focussing only on ven-
lafaxine,18,19 there is no up- to- date meta- analytical study 
investigating possible efficacy and effectiveness effect size 
differences from RCTs (including unpublished data) and 
non- RCTs of venlafaxine and duloxetine. Furthermore, only 
a small number of effectiveness studies were analysed in pre-
vious studies (eg Naudet et al. (2011)18). Therefore, a larger 
database, especially including more non- RCTs, is necessary 
for more reliable results. Moreover, predictors of these ef-
fects should be identified in order to gain a better understand-
ing of the effect size differences.
1.1 | Aims of the study
This study aimed at comparing pre- post effect sizes of RCTs 
and non- RCTs of duloxetine and venlafaxine trials based on 
a comprehensive meta- analysis. For a more thorough under-
standing of both study groups, key study characteristics and 
methodological quality are evaluated. Based on an explora-
tory approach, predictors that might explain divergencies in 
effect sizes are to be identified.
• RCTs and non- RCTs did not differ in external validity, questioning the common 
assumption of non- RCTs to be generally better suited to describe a drug’s effec-
tiveness in clinical practice.
• Improved descriptions and assessments of external validity are needed, in order to 
design more clinically relevant trials or to improve clinical practice to reach similar 
effects as in RCTs.
Limitations
• Our analyses are restricted to two antidepressants.
• As a result of the large number of included studies and varying study designs, high 
unexplained heterogeneity remained in our models.
• The subscale ‘external validity’ had very low variance and is therefore of limited 
value for the explanation of effect size differences.
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2 |  MATERIALS AND METHODS
This systematic review and meta- analysis followed an a 
priori defined protocol, which was published at the start of 
this project.20 This study is reported in accordance with the 
PRISMA guideline.21
2.1 | Study inclusion and exclusion criteria
The present systematic review and meta- analysis included 
RCTs, non- randomized controlled trials and observational 
prospective studies. Eligible studies examined the efficacy or 
effectiveness of duloxetine or venlafaxine in the acute treat-
ment of unipolar depression in adults (≥18 years). Included 
studies needed to provide sufficient outcome data of the de-
pression scale. No restrictions were defined for study type, 
patients’ comorbidities, trial duration, language, study or 
publication year, publication status, doses or dosing regimen. 
Exclusion criteria were as follows: studies in which dulox-
etine or venlafaxine were prescribed as adjunctive therapy, 
pooled analyses, double publications and studies for which no 
full- text publication was available (eg conference abstracts).
2.2 | Search strategy
For the present study, a sensitive search strategy was de-
veloped (Supplement material S1). Studies were selected 
with a systematic literature search in the electronic data-
bases EMBASE, Medline, PsycLit, PSYNDEXplus and the 
Cochrane Central Register of Controlled Trials. In order to 
include unpublished studies, additional hand searches were 
performed on the manufacturer databases (eg lillytrialguide.
com) and on study registry websites (eg clinicaltrials.gov). In 
addition, references to included studies were screened for po-
tentially relevant publications. The last update of the search 
was carried out in January 2020.
2.3 | Data extraction and management
Studies were independently selected by two researchers 
based on titles and abstracts with the aid of the defined inclu-
sion and exclusion criteria. After this screening, potentially 
relevant publications were examined for eligibility based on 
the full- text publication by one researcher and reviewed by a 
second one. Disagreements were resolved by the consultation 
of a third team member.
Data were extracted in a standardized Microsoft Excel 
sheet, which was developed based on trial reporting guide-
lines22,23 and on instruments assessing the quality of non- 
randomized trials.24 The extraction sheet comprised items 
for methods (study type, number of study centres, number 
of interventions, study duration), patient sample (number 
of participants, dropouts), interventions (type of drug, dose, 
dose regimen), outcome measures (means and standard de-
viations of baseline (pre- score) and endpoint (post- score)), 
change score of the outcome of depression symptoms and 
pre- post correlation (if reported). For depression scores, 
preference was given to the Hamilton Depression Rating 
Scale (HAMD)25 and after that to the Montgomery- Asberg 
Depression Rating Scale (MADRS)26 and other depression 
scales. In case of incompletely reported data, the respective 
authors were contacted. If essential endpoints were not avail-
able, studies were excluded from effect size estimations. For 
the assessment of the methodological quality of included 
studies, the Downs and Black (1998)27 scale was deployed, 
which includes subscales for reporting, external validity, bias 
and confounding.
2.4 | Data analysis
The primary outcome of this study was the pre- post effect 
size of the depression scale after acute therapy with dulox-
etine or venlafaxine. In order to estimate pre- post effect 
sizes, the standardized mean difference (SMD) of the base-
line depression score (pre) and the depression score after 
acute antidepressant therapy (post) was used. Effect sizes 
were standardized based on the standard deviations of the 
baseline depression score. Differences in effect size between 
efficacy and effectiveness trials were tested using a mixed- 
effects model with the ‘study design’ (RCTs vs. non- RCTs) 
as study- level moderator.
Missing standard deviations were imputed according to a 
validated method.28 In order to estimate the variance of the 
pre- post effect size, the correlations of baseline and post- 
intervention depression scores were taken into account. This 
correlation is hardly reported, and missing correlations were 
imputed from an individual patient data set of duloxetine tri-
als (n = 6890; r = 0.25 for HAMD and r = 0.21 for MADRS, 
unpublished data). Different versions of the HAMD scale 
were used in the included studies; if the item number was 
not reported in the primary study, it was estimated based on 
the baseline depression score. This estimation was necessary 
to calculate the depression severity as percentage of a stan-
dardized baseline score. Sensitivity analyses were conducted 
examining the impact of these imputations and estimations 
(pre- post correlations, standard deviations, HAMD items).
Study characteristics and methodological quality based 
on the Downs and Black (1998)27 scale of RCTs and non- 
RCTs were compared with Welch’s t tests and Pearson’s chi- 
squared tests, respectively.
In our protocol,20 we planned to develop a sum score 
based on the extracted data to describe proximity to clinical 
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routine conditions, but with the development of improved 
meta- analytic methods we found a multivariate predictor 
analysis to be more adequate than an analysis of an unval-
idated sum score. Therefore, we conducted an exploratory 
analysis of predictors within an information- theoretic ap-
proach.29,30 In detail, mixed meta- regression models with 
multiple predictors were fitted using maximum- likelihood 
estimation to predict standardized mean differences. 
Models were selected by the corrected Akaike information 
criterion (AICc) as decision criterion. As a result, the ‘best 
model’ and top models within two information criterion 
units of the best model were identified. For this purpose, 
the Akaike weights, that is the probability of a certain 
model to be the best model, were reported. Hence, the rel-
ative importance of each predictor (‘variable importance’) 
was calculated by summing up the weights of all models 
in which the predictor appeared. The often used cut- off at 
0.8 was used as orientation31 to distinguish the most rele-
vant variables from not so important ones. The inferences 
of all predictors across all models were estimated by a mul-
timodel inference approach.30
Predictors were selected based on an extensive literature 
search, clinical relevance and plausibility. As a result of this 
search, 11 predictors were included in the analysis: ‘study 
design’ (RCT/non- RCT), ‘depression severity’ (baseline 
depression score in % of the scale maximum), ‘dose’ (% of 
recommended maximum dose), ‘publication year’ (year of 
article publication or trial end year for unpublished stud-
ies), ‘number of participants’ (number of participants at 
randomization in a duloxetine or venlafaxine arm), ‘setting’ 
(inpatients/outpatients/in- and outpatients), ‘dropouts’ 
(number of dropouts of duloxetine or venlafaxine treat-
ment arm as percentage of the total number in the relevant 
treatment arm), ‘published’ (unpublished/published trial), 
‘medication’ (duloxetine/venlafaxine), ‘number of inter-
ventions’ (number of intervention arms in the study), ‘mul-
ticenter’ (yes/no). To compare duloxetine and venlafaxine 
doses, the percentage of the recommended maximum dose 
according to the U.S. Food and Drug Administration was 
analysed (120 mg/d for duloxetine; 225 mg/d for venlafax-
ine). The choice of 11 selected predictors resulted in 211 (= 
2048) possible models.
Potential publication bias was estimated by funnel plots 
and by Egger’s regression test, both for the total data set 
and for subgroups (RCTs/non- RCTs). For sensitivity anal-
yses, outliers were identified through visual inspection of 
Baujat plots32 and Cook’s distance measures. Furthermore, 
the impact of the imputations of pre- post correlations and 
missing standard deviations of the depression score as well 
as the impact of the estimation of HAMD items was eval-
uated in sensitivity analyses. We added a graphical post 
hoc analysis to explore the association of the Downs and 
Black (1998)27 subscale ‘external validity’ and effect sizes. 
Furthermore, we explored the differences between venla-
faxine and duloxetine trials post hoc by applying the model 
selection approach to each drug separately. To test a pos-
sible non- linear relationship of ‘dose’ and effect sizes, we 
performed an additional meta- regression with the variables 
identified as most important, including a quadratic polyno-
mial term for ‘dose’.
Data analyses were performed in R Studio using the 
‘metafor package’ and the ‘glmulti package’.33,34
3 |  RESULTS
3.1 | Characteristics of included studies
In total, the literature search yielded 1,848 records. 
Additionally, 45 records were identified through other 
sources (eg hand search, study registries, manufacturer da-
tabases). After the removal of duplicates, title and abstract 
screening as well as full- text revision, 245 studies met in-
clusion criteria and were analysed (Figure 1). Study charac-
teristics and full references of included studies are given in 
Supplement material S2 and S3.
The data set included 171 RCTs and 74 non- RCTs (non- 
randomized controlled trials and observational studies). 
Among them were 85 duloxetine and 164 venlafaxine trials. 
Four studies reported the effects for both duloxetine and ven-
lafaxine. Table 1 provides further characteristics of included 
studies.
3.2 | Study characteristics and 
methodological quality
Overall, most study characteristics in RCTs and non- RCTs 
were very similar. We were unable to identify any unpub-
lished non- RCT fulfilling our inclusion criteria. The number 
of treatment arms was significantly higher for RCTs than for 
non- RCTs, and the settings of the studies were significantly 
different between RCTs and non- RCTs (Table 1).
With regard to the Downs and Black (1998)27 scale, RCTs 
received significantly better ratings for the subscales ‘report-
ing’, and for the internal validity subscales ‘bias’ and ‘con-
founding’. However, no difference was found for the subscale 
‘external validity’ between the study types. We explored the 
association of the variable ‘external validity’ and the effect 
sizes in a scatter plot (Supplement material S4). The plot in-
dicates a very similar pattern of RCTs and non- RCTs in ex-
ternal validity ratings and revealed that, independent form the 
study type, the included studies received generally very low 
external validity ratings. Only nine studies (five RCTs35- 39 
and four non- RCTs40- 43) gained higher external validity 
scores (≥0.66).
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3.3 | Effect sizes
RCTs (SMD = −3.04, 95% CI = [−3.20; −2.88]; 165 stud-
ies; I2 = 96.43%) showed significantly higher (Δ = 0.41, 
p  =  0.012) pre- post effect sizes than non- RCTs (SMD = 
−2.62, 95% CI = [−2.90; −2.35], 64 studies, I2 = 97.94%) 
(Figure 2; for forest plots showing all included studies see 
Supplement material S5). Heterogeneity was very high in 
both groups.
3.4 | Mixed model meta- regression for 
predictor analyses
Model selection according to AICc identified the ‘best 
model’ and 4 other models within two information criterion 
units of the best model (Table 2). Model 1 had the highest 
weight with a probability of 5% to be the ‘best model’. All 5 
models contained the variables ‘depression severity’, ‘dose’, 
‘number of participants’, ‘dropouts’, ‘study design’ and ‘set-
ting’ while the predictor ‘publication year’ occurred in 3, and 
‘medication’ in 2 out of 5 models.
Through the examination across all models, the variables 
with highest importance across all models were identified 
(Figure 3). More specifically, the variables ‘depression sever-
ity’, ‘dose’ and ‘number of participants’ were most important 
and exceeded the cut- off for important variables, followed by 
‘dropouts’ and ‘study design’ with importance values slightly 
below the cut- off of 0.8.
Multimodel inference of all predictors across all models re-
vealed that the variables ‘depression severity’ and ‘dose’ were 
significant predictors for effect sizes of the depression score 
(p ≤ 0.05) with importance values close to 1 (Table 3). Studies 
with more severely depressed patients showed larger pre- post 
effect sizes, while studies with higher doses yielded smaller 
effect sizes. Multimodel inference shows no statistically sig-
nificant influence for the variables ‘study design’, ‘dropouts’ 
and ‘number of participants’ even though these variables show 
high importance values and occur in the best models. Studies 
with a higher rate of dropouts, larger numbers of participants 
and non- RCTs were associated with smaller effect sizes.
3.5 | Sensitivity analyses
Through Cook’s distance analyses and Baujat plots, eight 
studies44- 51 were identified as outliers and removed from anal-
yses for a sensitivity analysis. The meta- regression model was 
only slightly affected by the sensitivity analyses. The most no-
table change affected the variable ‘setting’ with a decrease in 
the importance score by 0.1 when outliers were excluded and 
0.2 when studies with imputed SD or with an unclear number 
of HAMD items were excluded. In addition, the latter analysis 
resulted in a slightly decreased importance of ‘study design’ 
(Δ = 0.1). Moreover, ‘study design’ was not included in all top 
models when outliers and when studies with unknown number 
of HAMD items were excluded. None of the subgroup analy-
ses affected the pre- post effect sizes markedly (Supplement 
F I G U R E  1  Flow chart of included 
studies.
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material S6.1, 6.3 and 6.4). Using the mean of reported pre- 
post correlations as imputation (r = 0.35 for HAMD and other 
scales, r = 0.36 for MADRS) did not suggest an influence on 
results (Supplement material S6.2).
Applying the model selection approach separately for 
venlafaxine and duloxetine revealed some differences for the 
drugs. For venlafaxine, ‘study design’ and ‘dose’ were identi-
fied as important and statistically significant predictors, while 
in the duloxetine data set only ‘depression severity’ reached 
the threshold of 0.8 and statistical significance. (Supplement 
material S6.5 and 6.6).
The meta- regression of the most important predictors in-
cluding a quadratic polynomial term for ‘dose’ marginally 
improved the AICc from 588.22 (linear model) to 587.83 
(quadratic polynomial model). However, in this model, both 
dose predictors (linear and quadratic) were no longer statis-
tically significant. Therefore, this model is not supporting a 
u- shaped relationship (Supplement material S6.7 and 6.8).
T A B L E  1  Characteristics of included studies.
Total (n = 245) RCTs (n = 171) non- RCTs (n = 74) Test statistics
Total number of participants 63,416 49,880 13,536
Drug, no. of studies (%)a 
Duloxetine 85 (34) 54 (31) 31 (43)
Venlafaxine 164 (66) 121 (69) 43 (57)
Sample size per arm, median (range) 84 (7– 3543) 114 (8– 821) 50 (7– 3543) t(78) = −0.44, p = 0.659
Sex (female) in % 65 65 66 t(109) = −0.57, p = 0.572
Age of participants, mean (SD) 46 (9.87) 45 (9.09) 47 (11.47) t(109) = −1.12, p = 0.267
Publication year, median (range) 2008 (1990– 2019) 2007 (1990– 2019) 2010 (1997– 2018) t(150) = −2.27, p = 0.247
Published, no. (%) 223 (90) 149 (85) 74 (100) χ2 (1) = 10.74, p = 0.001
HAMD- 17 at baseline, mean (SD) 
(n = 124)
22.66 (3.14) 22.81 (3.43) 22.32 (2.38) t(103) = 0.92, p = 0.360
Number of treatment arms, median 
(range)
2 (1– 8) 2 (1– 8) 1 (1– 5) t(203) = 13.43, p < 0.001
Dose, median % of maximum dose 
(range)
89 (14– 178) 75 (14– 178) 100 (17– 178) t(126) = −1.19, p = 0.235
Dosing regimen, number (%) χ2 (2) = 1.90, p = 0.386
Flexible 130 (52) 87 (50) 43 (58)
Fixed 104 (42) 78 (45) 26 (35)
Unclear 15 (6) 10 (6) 5 (7)
Trial duration in weeks, mean (SD) 8.54 (3.24) 8.38 (2.56) 8.93 (4.44) t(94) = −1.01, p = 0.317
Number of study centres, median 
(range)
11 (1– 836) 18.5 (1– 100) 1 (1– 836) t(49) = −0.22, p = 0.823
Setting, number (%b ) χ2 (3) = 17.53, p < 0.001
Inpatient 32 (13) 25 (14) 7 (9)
Outpatient 145 (58) 113 (65) 32 (43)
In- and outpatient 27 (11) 13 (7) 14 (19)
Unclear 45 (18) 24 (14) 21 (28)
Dropouts, mean % of participants 
treated with DLX/VEN (SD)
24.03 (14.43) 24.73 (13.15) 22.21 (17.29) t(91) =1.04, p = 0.299
Methodological quality, mean (SD)c 
Reporting 0.94 (0.16) 0.97 (0.15) 0.89 (0.17) t(127) = 3.10, p = 0.002
External validity 0.11 (0.19) 0.09 (0.18) 0.14 (0.21) t(118) = −1.64, p = 0.104
Bias 0.69 (0.13) 0.74 (0.12) 0.59 (0.10) t(166) = 9.53, p < 0.001
Confounding 0.62 (0.26) 0.72 (0.22) 0.40 (0.20) t(146) = 11.19, p < 0.001
DLX, duloxetine; VEN, venlafaxine.
aFour RCTs provided data for duloxetine and venlafaxine analyses. 
bNumbers may not sum up to 100% because of rounding. 
cDowns and Black (1998)27 subscales, higher values represent higher quality. 
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3.6 | Publication bias
The visual inspection of the funnel plots is indicative of pub-
lication bias for the full data set and each subgroup (RCTs/
non- RCTs). This is supported by the Egger's regression tests 
(each p > 0.001) (Supplement material S7).
4 |  DISCUSSION
This study aimed at (1) testing whether RCTs and non- RCTs 
on the treatment of depressive disorders with duloxetine and 
venlafaxine differ in pre- post effect sizes for depression rat-
ings, and (2) identifying predictors to explain differences in 
effect sizes.
The results confirmed the assumption of significantly 
larger effect sizes in RCTs compared to non- RCTs, which 
has been previously indicated in the literature.6,18,19 Although 
we were able to show a gap in effect sizes between RCTs 
and non- RCTs, study characteristics of RCTs and non- RCTs 
were very similar. Methodological evaluations suggested that 
internal validity and reporting quality received significantly 
higher ratings in RCTs than in non- RCTs, but the ratings 
for external validity did not differ between the groups with 
generally very low external validity ratings for both groups. 
Therefore, our results question the common assumption that 
non- RCTs have the advantage of providing higher external 
validity and being closer to clinical routine conditions.
We were able to identify predictors to explain effect size dif-
ferences, namely baseline ‘depression severity’, ‘dose’, ‘number 
F I G U R E  2  Forest plot of overall pre- 
post effect sizes of RCTs and non- RCTs; 
SMD, Standardized mean difference.
4 3 2 1 0
Standardized Mean Difference (SMD)
non RCTs
RCTs
2.63 [ 2.90, 2.35]







1 Depression severity + dose + no. of 
participants + dropouts + study design 
+ setting
Year 572.30 0.050
2 Year + medication 573.13 0.033
3 Year + published 573.15 0.033
4 573.52 0.027
5 Medication 573.53 0.027
AICc, corrected Akaike information criterion.
aModel = y ~ 1 + β0 + β1xi1 + … + βp′xip′ + ui with y as pre- post effect size of the depression score of the 
treatment with venlafaxine or duloxetine. 
bPredictors which occur in all 5 models. 
T A B L E  2  Top meta- regression modelsa 
within two information criterion units of the 
best model
F I G U R E  3  Model averaged 
importance of predictors. The vertical 
line shows the cut- off for most important 
variables.
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of participants’, ‘dropouts’, and ‘study design’. The variables 
‘number of participants’, ‘study design’ and ‘dropouts’ did not 
reach statistical significance, but showed high importance scores 
and occurred in all top models. Following suggestions for the in-
terpretation of results of information- theoretic approaches,29,30 
these predictors should also be considered.
Earlier research on the impact of ‘depression severity’ on 
effect sizes showed larger effects of antidepressant medica-
tion in more severely depressed patients.52- 54 In line with these 
studies, in our data, studies with more severely depressed pa-
tients showed larger effect sizes on the depression scale. Recent 
patient- level meta- analyses examining antidepressant- placebo 
differences found that the efficacy of this medication might be 
similar for different severity levels.55,56 While our results sug-
gest that the pre- post effect size is influenced by depression 
severity, comparative effect sizes may be unaffected.
Contrary to expectations, effect sizes were smaller in stud-
ies which report higher maximum doses. Current evidence of 
the dose- response relationship of antidepressants is limited 
and inconsistent. While some studies indicate a steady in-
crease in antidepressant response with higher doses,57 other 
findings suggest a stronger increase at smaller doses and 
a weaker increase58 or even a decrease in drug response at 
higher doses, that is an inverted u- shaped dose- response rela-
tionship.59 Even though a non- linear relationship is plausible, 
this was not reflected in our data. Moreover, a relationship 
of antidepressant dose and of the number of dropouts, which 
was defined as index of acceptability of a drug,59 is sug-
gested in the literature.59 In our study, the variable ‘dropouts’ 
achieved high importance scores. Higher dropout rates in 
the intervention arm were associated with lower effect sizes. 
Considering previous literature, an interaction effect with the 
variable ‘dose’ is possible and requires further consideration. 
However, meta- regressions including ‘dose’ on group level 
may be limited, thus making it necessary to examine the im-
pact of dose on effect sizes and drug’s acceptability in non- 
linear models with patient- level data.
In our data, studies with larger ‘numbers of participants’ 
were associated with smaller effect sizes. Previous research 
analysing placebo response rates found no influence of sam-
ple size on the effect sizes.31,60 Smaller trials have been 
shown to produce more variable effect sizes, and it has been 
suggested that more recent (and larger) trials have more sta-
ble placebo effects.61 Thus, controlled placebo trials may be 
different from our samples, which included some small un-
controlled studies with very large effect sizes.
The variable ‘study’ design occurred in all top models, but 
with regard to the overall importance and its changes in sensi-
tivity analyses, the picture is unclear. In line with effect sizes 
differing between RCTs and non- RCTs, ‘study design’ appears 
to be relevant when analysing predictors of effect size. However, 
other predictors discussed here seem to be more relevant.
Even though the variable ‘setting’ occurred in all top 
models in the main analysis, the variable declined in im-
portance values in most sensitivity analyses and no longer 
occurred in all top models. The importance score below the 
cut- off supports the assumption that this predictor is of minor 
importance in explaining effect sizes.
There are some other limitations in our study which have 
to be considered. Our analyses included only two antide-
pressants, duloxetine and venlafaxine, and may therefore not 
apply to other agents. Moreover, we analysed venlafaxine 
Estimate SE z Pr(>|z|) Importance
Intercept −32.657 27.936 −1.169 0.242 1.000
Depression severity −0.039 0.010 −4.081 0.000 0.999
Dose 0.006 0.002 3.263 0.001 0.990
No. of participants 0.000 0.000 1.546 0.122 0.822
Dropouts 0.008 0.006 1.424 0.154 0.793
Study designa 0.292 0.210 1.386 0.166 0.781
Settingb 0.043 0.034 1.258 0.208 0.745
Publication year 0.015 0.014 1.074 0.283 0.679
Medication 
(Duloxetine)c 
0.091 0.138 0.662 0.508 0.440
Publishedd −0.074 0.146 −0.506 0.613 0.338
No. of interventions −0.009 0.033 −0.289 0.772 0.295
Multicentree 0.003 0.010 0.267 0.789 0.263
a1 = efficacy vs. 2 = effectiveness. 
b1 = inpatients. 2 = outpatients. 3 = in- and outpatients. 9 = unclear. 
c1 = yes (Duloxetine). 2 = no (Venlafaxine). 
d0 = no. 1 = yes. 
e0 = no. 1 = yes. 9 = unclear. 
T A B L E  3  Inference of all a priori 
selected predictors across all models.
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and duloxetine data in one analysis. As ‘medication’ was not 
identified as an important predictor in our primary analysis, 
our results suggest that pre- post effect sizes depend less on 
medication than on other predictors. However, separate anal-
yses of the data sets for each medication revealed some dif-
ferences in predictor models. Considering the large number 
of predictors and the limited sample sizes for each of these 
data sets, we find these results not surprising. We assume that 
they reflect differences of the predictors’ variances in duloxe-
tine and venlafaxine data sets.
The information- theoretic approach used to examine pre-
dictors combines several advantages, but does not consider 
model validity and highly depends on an appropriate prese-
lection of predictors.30 Even though predictors were carefully 
selected, the set of potential predictors is somehow arbitrary; 
thus, it cannot be ruled out that a different selection might 
have led to different results.
Furthermore, the studies included were highly heteroge-
neous, even within the predictor analysis. The current study 
comprises a large number of trials with varying study designs; 
thus, substantial heterogeneity was expected.62 Our analyses 
also suggest a significant publication bias for RCTs as well as 
for non- RCTs studies. Furthermore, the funnel plots suggest 
a stronger publication bias for non- RCTs than for RCTs and 
we were unable to identify any unpublished non- RCT.
External validity was rated low for the majority of studies 
in both groups. Thus, the subscale had very low variance and 
is therefore of limited value for the explanation of effect size 
differences. We used the Downs and Black (1998)27 scale for 
our analyses, because there is a lack of evaluated instruments 
allowing the comparison of RCTs and non- RCTs. However, 
especially for the assessment of external trial validity, more 
sophisticated instruments to determine proximity to clinical 
reality should be developed.
The variable ‘dose’ was analysed as percentage of the max-
imum recommended dose. As mean doses are hardly reported 
(especially in non- RCTs), we assumed this operationalization to 
be the best approximation of drug dose. However, it is possible 
that, especially in non- RCTs or in studies with flexible dosing 
regimen, the reported possible maximum dose was not neces-
sarily the dose taken by patients, as was shown recently.63 As 
mentioned before, there is a need to replicate the influence of 
dose on effect sizes using individual patient data meta- analyses.
Moreover, the variable ‘depression severity’ was included 
as percentage of the scale maximum at baseline to allow com-
parisons across different scales. We included studies using the 
HAMD and MADRS, and one could argue that scales with dif-
ferent maxima have different cut- offs to distinguish mild, mod-
erate and severe depression. However, cut- offs for depression 
severity have been shown to be very similar for HAMD and 
MADRS scores in comparison to the relevant scale maxima.64
In conclusion, our results show that RCTs and non- RCTs 
differ in effect sizes with RCTs showing larger treatment 
effects than non- RCTs. Furthermore, results reveal that ex-
ternal validity in non- RCTs was not superior to RCTs. In line 
with this, data show that different study designs (RCTs vs. 
non- RCTs) were very similar with respect to most study char-
acteristics. Thus, other variables are likely to influence effect 
sizes. Predictor analyses revealed that the variables baseline 
‘depression severity’, ‘dose’ and ‘number of participants’ are 
most important predictors of effect sizes, followed by ‘drop-
outs’, while the importance of the variable ‘study design’ 
remains unclear. In summary, we identified variables that 
predict antidepressant effect sizes but these variables were 
not necessarily descriptive attributes associated with ‘study 
design’ (RCT or non- RCT).
Our results question the common assumption that non- 
RCTs are generally better suited to describe a drug’s effec-
tiveness in clinical practice than RCTs. In our study sample, 
non- RCTs did not show a significant advantage over RCTs 
in terms of external validity but were rated to be lower in in-
ternal validity and reporting quality. Thus, to achieve clinical 
relevance, a careful assessment of both internal and external 
study validity is required. The low external validity of RCTs as 
well as of non- RCTs limits the understanding of whether or not 
clinical studies offer a realistic assessment of effects in clinical 
practice. A better understanding would help us design trials 
that are better suited to inform clinical practice and, perhaps, 
improve clinical practise to achieve stronger treatment effects.
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